Key Drivers
- Strong margins
- Robust FCF
- High intangibles
AIAI Summary
Agilent should be viewed as shifting from a high‑margin instruments vendor to a hybrid diagnostics/services and CDMO platform—improving revenue durability but making the investment thesis hinge on successful integration of Biocare/CDMO and continued strong FCF conversion to justify its premium multiple. Monitor quarterly operating cash‑flow conversion, margin uplift from Ignite, and early Biocare/CDMO synergy/revenue milestones (and treat a sustained cash conversion shortfall or impairment as a clear sell trigger).
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Robust FCF
- •High intangibles
A combines strong margins, healthy FCF and moderate leverage with solid returns but carries valuation risk and balance-sheet concentration in intangibles that warrant monitoring. #solid-margins #high-intangibles
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support band
- •High volatility
Over the last month the price fell ~9.6% from $122.90 to $111.30, registering lower highs, a support band at $111.30–$111.63 and resistance at $118–$125, so failure of support risks continuation while a hold could attract mean‑reversion buying.
Rapid swing from ~$148 in
Sentiment & News
Key News Insights:
- •Modest revenue growth
- •Margin pressure
- •Biocare acquisition
Agilent posted modest Q1 revenue growth with a slight EPS miss and margin pressure due to operational disruptions, while advancing strategic M&A (Biocare) and CDMO expansion amid mixed institutional flows. #M&A
Strategic deals and CDMO expansion underpin medium‑term growth, but near‑term margin and execution risks should keep the stock volatile
Similar Companies in Healthcare
Other companies in the same sector with AI ratings